& Darnerud, P
doi: 10.21037/gs.2019.12.03 [DOI] [PMC free article] [PubMed] [Google Scholar] 9.Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al
Pentapharms key contributions to Syn-AKE development include: Isolation and characterization of Waglerin-1 from Temple Viper venom as the neuromuscular-active component Development of synthetic peptide mimetics capturing essential bioactivity while eliminating toxicity Optimization of peptide sequence (beta-Ala-Pro-Dab-NHBzl) for topical penetration and stability Formulation research establishing optimal concentrations and delivery systems Safety profiling and initial efficacy studies supporting cosmetic applications Patent protection (2006) enabling commercial development and widespread research use Following Pentapharms acquisition by DSM-Firmenich, Syn-AKE became part of a broader cosmetic peptide portfolio
doi: 10.1016/j.clnu.2018.11.032 120
Your medication will arrive to you within 5 business days from when your prescription request was submitted
they're about unleashing a vibrant, energetic version of yourself